Conference Program

Best of ASCO® Bangkok 2018

3-4 August 2018 at Ballroom 1, Shangri-La Hotel Bangkok, Thailand

Download : PDF version (Save target as, Save link as)
       Day 1_Program BOA 2018
       Day 2_Program BOA 2018

August 3-4, 2018
Shangri-La Hotel Bangkok
Ballroom 1
Bangrak, Bangkok, Thailand

Online Registrationto attend BOA Bangkok 2018

Tentative Program: Best of ASCO Bangkok 2018 (Day 1: 3rd August 2018)

Time Abstract ID Title Presenter Moderator
7.30-8.30 Trainee session
(Thai language)
Personalized Approach to Systemic Therapy of Renal Cancer Assist Prof. CHANYOOT  BANDIDWATTANAWONG
8:30-9:30 Trainee session
(Thai language)
Point/Counterpoint: Next-Generation Sequencing—Is It Right for Every Patient? Asst.Prof SUEBPONG TANASANVIMON
9:30-9:40 Opening and welcome message Assoc.Prof.VIROTE SRIURANPONG 
    Scientific Agenda   Assoc.Prof.SUTHINEE ITHIMAKIN
9:45-10:30   Symposium Amgen: How to optimize treatment outcome in RAS WT mCRC in first line setting : A key learning from expert Assoc.Prof. PETER GIBBS, MBBS, FRACP, MD,
Walter and Eliza Hall Institute and Western Hospital, Melbourne, Australia
10:30-10:50   Exhibition    
    Colorectal cancer session     
10:50-11:00 3501 Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer.  Assist.Prof. KRITTIYA KORPHAISARN Prof.VORACHAI RATANATHARATHORN
11:00-11:10 3505 First-line FOLFOX plus panitumumab followed by 5FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.  KULATIDA MANEENIL, M.D.  
11:10-11.20 LBA3503 A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.  Assist.Prof.KRIT KITISIN   
11:20-11:40   Discussion/ Q&A  Discussant: Prof.PETER GIBBS, Q&A: panelists   
11:45-12:30   Symposium Novartis: Management in HR+ breast cancer JOO HYUK SOHN, M.D.PH.D.
Division of Medical Oncology,
Severance Breast Cancer Clinic,
Yonsei Cancer Center, Korea
12:30-12:50   Exhibition    
    Breast cancer session    
12:50-13:00 LBA1 TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptorpositive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score.  Assist.Prof.THITIYA  DEJTHEVAPORN Assoc. Prof. VICHIEN  SRIMUNINNIMIT
13:00-13:10 500 Adjuvant denosumab in early breast cancer: Disease free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.  Assoc.Prof.SUTHINEE ITHIMAKIN  
13:10-13:20 502 Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study. Assoc.Prof.PATRAPIM SUNPAWERAVONG  
13:20-13:40 Discussion/ Q&A  Discussant: Assist.Prof.AUMKHAE SOOKPRASERT, Q&A: panelists  
13:40-13:50 506 PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 noninferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.  Assist.Prof.AUMKHAE  SOOKPRASERT  
13:50-14:00 1000 Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3 PIYAWAN TIENCHAIANANDA, M.D.  
14:00-14:10 LBA1006 Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer: Primary analysis from SANDPIPER NAPA PARINYANITIKUL, M.D.  
14:10-14:30   Discussion/ Q&A  Discussant: Prof.ADAM BRUFSKY, Q&A: panelists   
14:35-15:20   Symposium Roche: The expanding frontier with CIT in lung cancer  Prof.Dae Ho Lee
University of Ulsan College of Medicine,
Asan Medical Center, Korea
15:20-15:40   Exhibition     
  Supportive care and survivor care  
15:40-15:52 10000 Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).  Assoc.Prof.SUTHINEE ITHIMAKIN Assoc.Prof.BUSYAMAS CHEWASKULYONG
15:52-16:04 LBA10003 Improving Communication with Older Patients with Cancer using Geriatric Assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) Cluster Randomized Controlled Trial (CRCT).  Assoc.Prof.KOSIN WIRASORN  
16:04-16:16 10005 Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Cancer PIYAWAN TIENCHAIANANDA, M.D.  
16:16-16:30 Q&A   
16:35-17:20   Symposium Pfizer: Constructing a new future in breast cancer treatment: Focusing on HR+ HER2- mBC Prof.ADAM BRUFSKY
University of Pittsburgh, USA
End of day 1

Tentative Program: Best of ASCO Bangkok 2018 (Day 2: 4th August 2018)

Time Abstract ID Title Presenter Moderator
8:00-8:45   Symposium BMS: The Evolving Immuno-Oncology Treatment Landscape in NSCLC and Head and Neck Cancers Assist.Prof.THORSTEN FUREDER
University of Vienna, Austria
    Head and neck cancer session     
8:45-8:55 6000 Results of a randomized phase III study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.  CHANIDA VINAYANUWATTIKUN, M.D. Assist.Prof.CHARUWAN AKEWANLOP
8:55-9:05 6006 Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP).  DANITA KANNARUNIMIT, M.D.  
9:05-9:15 6008 Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC).  Assist.Prof.NUTTAPONG NGAMPHAIBOON  
9:15-9:35   Discussion/ Q&A  Discussant: Assist.Prof.THORSTEN FUREDER, Q&A: panelists  
9.40-10.25   Symposium Eisai: HCC management: Current and beyond Prof.CHIUN HSU
Institute of Oncology, College of Medicine, National Taiwan University, Taiwan 
10.25-10.45   Exhibition     
    Non-colorectal gastrointestinal cancer session    
10:45-10:55 LBA4001 Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.  Assist.Prof. SUEBPONG TANASANVIMON Assist.Prof.EKAPHOP SIRACHAINAN
10:55-11:05 4007 A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial). Assist.Prof.NUTTAPONG NGAMPHAIBOON  
11:05-11:15 4003 REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. NAIYARAT PRASONGSOOK, M.D.  
11:15-11:35   Discussion/ Q&A  Discussant: Prof.CHIUN HSU, Q&A: panelists  
  Genitourinary cancer session  
11:35-11:47 LBA3 CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.  Assist.Prof.THITIYA  DEJTHEVAPORN KASAN SEETALAROM, M.D.
11:47-11:59 4500 Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427.  PONGWUT DANCHIVIJITR, M.D.  
11:59-12:11 5000 A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.  Assoc.Prof.CHAIYUT CHAROENTUM  
12:11-12:25 Q&A     
12:30-13:15   Lunch symposium MSD: A Renaissance of Checkpoint Immunotherapy in Advanced NSCLC treatment Clinical Assoc.Prof. JAMES HO
Department of Medicine, The University of Hong Kong
13:15-13:30   Exhibition     
    Lung cancer session    
13:30-13:40 LBA9000 IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC.  NAIYARAT PRASONGSOOK, M.D. Assoc.Prof.VIROTE SRIURANPONG
13:40-13:50 LBA4 Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.  Assist.Prof.THANYANAN REUNGWETWATTANA  
13:50-14:00 9001 Nivolumab+ platinum-doublet chemotherapy vs chemotherapy as first line treatment for advanced NSCLC with <1% tumor PDL-1 expression: Results from Checkmate 227 CHANIDA VINAYANUWATTIKUN, M.D.  
14:00-14:20 Discussion/ Q&A  Discussant:
Assist. Prof.CHARUWAN AKEWANLOP, Q&A: panelists
14:20-14:30 9006 Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026.  PIYADA SITTHIDEATPHAIBOON, M.D.  
14:30-14:40 9003 Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC. SIRIWIMON  SAICHAMCHAN, M.D.  
14:40-14:55   Discussion/ Q&A  Discussant: Clinical Assoc.Prof. JAMES HO , Q&A: panelists  
15:00-15:45   Symposium AstraZeneca: Current and future treatment in HR+ advance breast cancer Dr. NAN SOON WONG
National Cancer Center Singapore, Singapore
15:45-16:00   Exhibition    
  Melanoma and sarcoma session  
16:00-16:12 9502 Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).  Assoc.Prof.PATRAPIM SUNPAWERAVONG Clin.Prof. SUDSAWAT LAOHAVINIJ
16:12-16:24 11500 Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). Assist Prof. CHANYOOT  BANDIDWATTANAWONG  
16:24-16:36 11503 Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial. TOUCH ATIVITAVAS, M.D.  
16:36-16:50 Q&A   
16:50   Closing Remark   Assoc.Prof.VIROTE SRIURANPONG